Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isomazole SCHEMBL30578156 | 1.00 | PDE5A (0.51) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| Isomazole SCHEMBL121627 | 0.99 | PDE5A (0.51) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| Isomazole SCHEMBL9634750 | 0.91 | PDE5A (0.46) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| Isomazole SCHEMBL9634760 | 0.91 | PDE5A (0.46) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL7280738 | 0.91 | PDE5A (0.50) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL9636112 | 0.88 | PDE5A (0.41) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL7270954 | 0.88 | PDE5A (0.48) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL9634671 | 0.87 | PDE5A (0.39) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL7272018 | 0.86 | PDE5A (0.47) | PDE5APDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL7272064 | 0.86 | PDE5A (0.48) | PDE5APDE3BPDE3AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| EP-2275095-A2 | Neurogenesis by muscarinic receptor modulation | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009141627-A1 | TREATING NIEMANN-PICK DISEASE TYPE C AND RELATED DISORDERS BY ELEVATING INTRACELLULAR CALCIUM | ISIS INNOVATION LIMITED (GB) | 2009-11-26 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-4904785-A | INOTROPIC AGENTS FOR CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 1990-02-27 | — | — | US | claimed |
| US-4868182-A | HYPOTENSIVE AND CARDIOTONIC, SYNERGISTIC | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-19 | — | — | US | claimed |
| US-4758574-A | 2-phenylimidazio (4,5-c) pyridines | ELI LILLY AND COMPANY (US) | 1988-07-19 | — | — | US | claimed |
| EP-0268146-A1 | Enhancement of prazosin | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-05-25 | — | — | EP | claimed |
| EP-0266897-A1 | Synthesis of alkylsulfinyl substituted 2-phenylimidazo [4,5-c] pyridines | ELI LILLY AND COMPANY (US) | 1988-05-11 | — | — | EP | claimed |
| US-4740599-A | Synthesis of alkylsulfinyl substituted 2-phenylimidazo(4,5-c)pyridines | ELI LILLY AND COMPANY (US) | 1988-04-26 | — | — | US | claimed |
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | claimed |
| US-4603139-A | 2-PHENYL-1H-IMIDAZOL(4,5-C)PYRIDINES, ANTICXOAGULANTS, CARDIOVASCULAR DISORDERS | BURROUGHS WELLCOME CO. | 1986-07-29 | — | — | US | claimed |
| EP-0093593-A2 | Pyridine compounds | ELI LILLY AND COMPANY (US) | 1983-11-09 | — | — | EP | claimed |
| EP-0079083-A1 | New imidazo[4,5-c]pyridine derivatives, processes for their preparation and pharmaceutical formulations containing such compounds | MERCK PATENT GmbH (DE) | 1983-05-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE5A 3481/4885PDE3B 2328/4885PDE3A 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.